188 EAST BLAINE STREET, SUITE 400, SEATTLE, WA
Sana Biotechnology Elects Class II Directors at 2026 Annual Meeting
Other Events
Reports First Quarter 2026 Financial Results and Business Updates
Annual Report to Security Holders
Director Resignation and Re-appointment of Steven D. Harr, M.D.
Stock Purchase Agreement with Mayo Clinic for $25 Million in Shares
Earnings Release
Appoints Brian Piper as Executive Vice President, Chief Financial Officer
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement
Free Writing Prospectus